AbsoluteCare Secures $135M in Strategic Investment
Deal News | Jul 31, 2025 | TT Capital Partners LLC
The article provides a comprehensive overview of recent merger, acquisition, and investment activities within the healthcare sector, highlighting the dynamic changes and innovations driving the industry forward. Key transactions include AbsoluteCare's $135 million strategic investment from a consortium of investors, Avalyn's $100 million Series D financing for inhaled therapies for Pulmonary Fibrosis, and Iodine Software's acquisition by Waystar at an enterprise value of $1.25 billion. Highlights also feature the acquisition of CHS's laboratory services by Labcorp for $195 million, Dispatch Bio's $216 million Series A launch for universal cancer treatments, and Crossroads Treatment Centers' expansion through the acquisition of Family Health Services. The article encapsulates a period of significant activity underscoring the strategic realignments and capital inflows transforming healthcare.
Sectors
- Healthcare
- Private Equity & Venture Capital
Geography
- United States – Many of the companies and transactions listed are based in or directly involve entities operating within the United States.
Industry
- Healthcare – The article focuses on various mergers, acquisitions, and investments within the healthcare sector, indicating significant activity and transformation in this industry.
- Private Equity & Venture Capital – Many transactions involve financial backing from private equity firms and venture capitalists, illustrating their active role in shaping the healthcare landscape.
Financials
- $135 million – Amount secured by AbsoluteCare in equity financing.
- $100 million – Amount raised by Avalyn in Series D financing.
- $1.25 billion – Enterprise value for the acquisition of Iodine Software by Waystar.
- $195 million – Purchase price for Labcorp's acquisition of assets from Community Health Systems.
- $216 million – Series A funding raised by Dispatch Bio.
- $475 million – Acquisition price for iTeos Therapeutics by Concentra Biosciences.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| AbsoluteCare | Target Company | Company | Healthcare provider securing $135 million in strategic investment. |
| Kinderhook Industries, CVS Health Ventures, Pacific Life, Lexington Partners | Investors | Company | Investors involved in AbsoluteCare's strategic equity financing. |
| Avalyn | Target Company | Company | Recipient of $100 million Series D financing for clinical development. |
| Suvretta Capital Management, SR One | Investors | Company | Co-leads of Avalyn's Series D financing round. |
| BetterRX | Target Company | Company | Received a strategic growth investment from BVP Forge. |
| BVP Forge | Investor | Company | Investor in BetterRX growth investment. |
| BRM Specialty Markets | Selling Company | Company | Acquired by Sands Point Risk. |
| Sands Point Risk | Buyer | Company | Acquirer of BRM Specialty Markets. |
| Community Health Systems | Selling Company | Company | Selling select assets and leases to Labcorp. |
| Labcorp | Buyer | Company | Acquiring select assets from CHS in a $195 million transaction. |
| Iodine Software | Target Company | Company | Healthcare AI company to be acquired by Waystar. |
| Waystar | Buyer | Company | Acquiring Iodine Software from Advent International. |
| Advent International | Selling Company | Company | Current owner of Iodine Software. |